Phase III, Double-Blind, Placebo-Controlled Study of Dail Everolimus in Combination with Trastuzumab and Vinorelbine in Pretreated Women with HER2/newu Over-Expressing Locally Advanced or Metastatic Breast Cancer

Phase III Randomized, Double-Blind Study Cmoparing METMAb + Bvacizub + Paclitaxel and MetMab + Placebo + Paclitaxel Relative to Placebo + Bevacizumab + Placlitaxel, in the 1st and 2nd Line Treatment of Metastatic or Locally Recurrent, Triple-Negative Breast Cancer

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Denosumab as Adjuvant or Neoadjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-Care)

A Phase III Randomized, Multcenter, Two-Arm Open-Label Trial To Evaluate the Efficacy of T-DM1 cmopared with treatment of physician's choice in patients with HER2-Positive Metastatic Breast Cancer who have received at least two prior regimens of HER2-Directed Therapy

Phase III, Study to evaluate the efficacy and the safety of T-DM1 Combined with pertuzumab vs T-DM1 (Blinded for Pertuzumab), vs Trastuzumab plus Taxane, as 1st Line Treatment in HEr-2 Positive Metastatic Breast Cancer.

Phase IV, Open-label, Study of the anti-cancer effects of Zoledronic Acid in combination with CHemotherapy +/- Avastin or Hormonal Therapy using Circulating Tumor Cell Measurements (CTC'S) in the 1st Line and 2nd Line Treatment of patients with HER2-negative MBC without Bone Metastases

A Phase I/II Study to assess the safety and therapeutic effect of INCB007839 in combination with Transtuzumab and vinorelbine metastatic HER2 + MBC

Phase II, Double-Blind, Study of the continued efficacy and safety of Zometa (every 4 weeks vs. every 12 weeks) in patients with documented bone metastases from Breast Cancer

Phase III Double Blind Trial of Capecitabine plus Sorafenib vs. Capecitabine plus placebo in the t1st and 2nd Line Treatment of Locally advanced or Stage IV HER 2 Negative Breast Cancer

A Randomized Phase II Study of Bevacizumab/mFOLFOX vs Bevacizumab/Folfiri with Biomarker Stratification in Patients with Previously Untreated Metastatic Colorectal Cancer

Phase 1/2 Trial of Placebo-Controlled, ARQ 197 in Combination with Irinotecan and Cetuximab in the Treatment of Subjects wtih Metastatic Colorectal Cancer with Wild-Type DRAS who have received Front-Line Systemic Therapy

Randomized, Multicenter, Double-Blind, Phase III Trial of Tavocept vs. Plaebo in Patients with Newly Diagnosed or Relapse Advanced Primary Adenocarcinoma of the Lung Treated with Docetaxel or Paclitaxel + Cisplatin

Phase 1b/2 Randomized Study of MEDI-575 in combination with Carboplatin plus Paclitaxol vs. Carboplatin Plus alone in 1st Line Treatment of Advanced NSCLC

Phase III Randomized Study to assess the efficacy and Safety of Perifosine added to the Combinatino of Bortezomib and Dexamethasone in Multiple Myeloma Patients previously Treated with Bortezomib

The multiple Myeloma Disease Registry

A phase I/II Study of Immunotherapy with Humanized Anti-CD20 Antibody, Immu-106 (hA20) in Adult Patients with Chronic ITP

Randomized, Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in patients with Aggressive B-Cell NHL who have relpased after therapy with CHOP-R or an Equivalent Regimen and are inelligible for Stem Cell Transplant.

Phase III Randomized, Open Label Study of Single Agent Ofatumamab vs. Single Agent Rituximab in Follicular Lymphoma relapsed after Rituximab-Containing Therapy.

Phase III Randomized Study of Weekly ABI-007 Plus Gemcitabine vs. Gemcitabine Alnoe in 1st Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma.

Phase II Open-Label, Multicenter Study Comparing CO-1.01 with Gemcitabine as 1st Line Treatment in Metastatic Pancreatic Adenocarcinoma

Phase II Open-Label, Multicenter Study Comparing CO-1.01 with Gemcitabine as 1st Line Treatment in Metastatic Pancreatic Adenocarcinoma

Phase II Open Label, Trail of Gemcitabine with or without Bavituximab in 1st Line treatment of Metastatic Pancreatic Adenocarcinoma

Phase 2b Randomized, Dose Escalation study of the Safety and exploratory Efficacy of Kanglaite Injection plus Gemcitabine (G+K) vs Gemcitabnie in the 1st line treatment of patients with Advanced Pancreatic Cancer

A Randomized Study of the JAK Inhibitor INCB018424 Tablets compared to Best Available Therapy in subjects wtih Polycythemia Vera Who are Resistant to Hydroxyurea

A Randomized, Double Blinded, Phase III Trial to Compare the efficacy of Ipilimumbab vs. Placebo in Asymptomatic or Minimally Symptomatic Patients with Mestastatic Chemo-Naive CRPC

Phase III Randomized, Double-Blind, Placebo-Controlled to assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in subjects with Platinum-Sensitive Ovarian Cancer in First Relapse.

Phase III Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (Farletuzumab) in combination with Paclitaxel in subjects wtih Platinum-resistant or Refractory Relapsed Ovarian Cancer

Phase I/II Study of Disulfiram, Capecitabine and Copper Gluconaet for the treatment of Refractory Solid Tumors.